Q-omics provides the consensus-scored TRIM7 profile across patient tissues and cancer cell-line models. TRIM7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TRIM7 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, TRIM7 RNA expression shows 15,836 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, LIHC, and ACC as cancer lineages where TRIM7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM7 survival associations across molecular data types. TRIM7 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM7 RNA expression–survival associations across cancer types. High TRIM7 expression shows unfavorable associations in LUAD, ACC, SCLC and LIHC, but favorable associations in KIRC and LUSC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TRIM7 RNA expression.
This table summarizes TRIM7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TRIM7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM7 shows lower tumor expression in BRCA and higher tumor expression in LIHC, LUSC, COAD, BLCA and KICH. The LIHC box plot shows higher TRIM7 RNA expression in tumor versus normal tissue (log2 FC = +0.484, t-test p < 0.001).
This table shows molecular features associated with TRIM7 in patient tissues and cancer cell lines. In patient samples, TRIM7 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
